1. Academic Validation
  2. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

  • EMBO Mol Med. 2018 Nov;10(11):e9316. doi: 10.15252/emmm.201809316.
Ulf Neumann 1 Mike Ufer 2 Laura H Jacobson 3 Marie-Laure Rouzade-Dominguez 2 Gunilla Huledal 4 Carine Kolly 5 Rainer M Lüönd 6 Rainer Machauer 6 Siem J Veenstra 6 Konstanze Hurth 6 Heinrich Rueeger 6 Marina Tintelnot-Blomley 6 Matthias Staufenbiel 3 Derya R Shimshek 3 Ludovic Perrot 3 Wilfried Frieauff 5 Valerie Dubost 5 Hilmar Schiller 4 Barbara Vogg 4 Karen Beltz 4 Alexandre Avrameas 7 Sandrine Kretz 7 Nicole Pezous 2 Jean-Michel Rondeau 8 Nicolau Beckmann 9 Andreas Hartmann 5 Stefan Vormfelde 2 Olivier J David 10 Bruno Galli 10 Rita Ramos 10 Ana Graf 10 Cristina Lopez Lopez 11
Affiliations

Affiliations

  • 1 Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland ulf.neumann@novartis.com cristina.lopez_lopez@novartis.com.
  • 2 Translational Medicine, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 3 Neuroscience, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 4 PK Sciences, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 5 Preclinical Safety, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 6 Global Discovery Chemistry, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 7 Biomarker Discovery, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 8 Chemical Biology and Therapeutics, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 9 Musculoskeletal Diseases, Novartis Institute for BioMedical Research, Basel, Switzerland.
  • 10 Global Drug Development, Novartis, Basel, Switzerland.
  • 11 Global Drug Development, Novartis, Basel, Switzerland ulf.neumann@novartis.com cristina.lopez_lopez@novartis.com.
Abstract

The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of Amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE-1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose-dependent Aβ reduction in the cerebrospinal fluid. Thus, long-term, pivotal studies with CNP520 have been initiated in the Generation Program.

Keywords

Alzheimer's disease; BACE‐1 inhibitor; drug discovery; prevention; β‐amyloid.

Figures
Products